Bone disease induced by phenytoin therapy: clinical and experimental study.
Previous studies have made references to prolonged treatment with phenytoin as a possible risk factor in the development of osteoporosis and/or osteomalacia. We studied a group of 30 epileptic patients who were under long-term treatment with phenytoin (DPH) in an ambulatory regimen. We found the prevalence of osteoporosis to be 3.3% and of osteopenia to be 56.6%, affecting predominantly the femur, without any significant decrease in bone mineral density of the lumbar spine. These patients were showing signs of bone turnover uncoupling with increases in bone resorption markers. At this time, they also exhibited slight alterations in their phosphocalcium metabolism with trends to hypocalcemia and secondary hyperparathyroidism that was found not to be caused by a vitamin D deficiency as the serum levels of 25(OH)D and 1,25(OH)(2)D were normal. With the aims of corroborating these results and to investigate the physiopathological effects on the bone induced by anticonvulsant drugs we developed a further experimental study in which we administered DPH over a 6-week period with a dose of 5 g/kg/day to male Wistar rats that were in the growth phase. This treatment produced a decrease in overall BMD and bone mineral content in the femur. We did not find osteomalacia in the vertebral biopsy, but the administration of DPH to these animals decreased trabecular volume as well as lessened the thickness of osteoid edges together with an uncoupling in bone turnover. There was also a marked decrease in bone formation and a tendency towards increased bone resorption. We have also found a decrease in resistance to fracture by torsion in the biomechanical assay, which translates into an increase in bone fragility. In these male Wistar rats, the administration of DPH produced a tendency towards increasing the markers of resorption and, though changes in serum levels of calcium and phosphorus were not observed, to provoke an increase in the parathyroid hormone levels; with normal levels of 1,25(OH)(2)D which has produced the same inclination in rats as in humans.
Moro-Alvarez
M J
MJ
Internal Medicine, Metabolic Bone Disease Unit H, Central Cruz Roja, Madrid, Spain. mjmoro.hccruzr@salud.madrid.org
Díaz Curiel
M
M
de la Piedra
C
C
Mariñoso
M L
ML
Carrascal
M T
MT
D000328:Adult; D000368:Aged; D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D001851:Bone Diseases, Metabolic / Q000097:blood / Q000139:chemically induced*; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy; D005260:Female; D005269:Femur / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D008903:Minerals / Q000378:metabolism; D018579:Patient Selection; D010672:Phenytoin / Q000009:adverse effects* / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D013131:Spine / Q000187:drug effects / Q000378:metabolism; D054159:Torsion, Mechanical
D008903:Minerals; D010672:Phenytoin